$0.6 Earnings Expected For Abbott Laboratories (NYSE:ABT)

Sell-side analysts on Wall Street are anticipating that Abbott Laboratories (NYSE:ABT) will report earnings of $0.43 per share when the company issues their quarterly report today.  This is the consensus EPS number according to data from Zack’s Research.  How the estimated EPS differs from the actual earnings number is what investors will be paying particularly close attention to. 

Most recently Abbott Laboratories (NYSE:ABT) reported a surprise factor of 11.63%. The actual number was $0.05 away from the Zacks consensus just prior to the actual release. A significant surprise factor can lead to stock swings in the price in the hours and days following the earnings report.

Projected Stock Movement
Research analysts covering shares of Abbott Laboratories (NYSE:ABT) are anticipating on a consensus basis that the stock will reach $52.153 within the next 52 weeks. Of the analysts providing short term targets, the most bullish analyst has a $58 target on the stock. On the other end, the most conservative has a short term target of $48. This is based on the 13 analysts taken into consideration by Zacks. The consensus price target was last revised on 2017-07-17.

Zacks also provides a simplified scale for analyst recommendations. They use a one to five scale where they translate brokerage firm Buy/Sell/Hold recommendations into an average broker rating. A low number in the 1-2 range typically indicates a Buy, 3 represents a Hold and 4-5 represents a consensus Sell rating. Abbott Laboratories (NYSE:ABT) currently has an ABR of 1.59 heading into today’s announcement. This number is also based on the 13 sell-side firms polled by Zacks.

Value investors may be scanning the shelves for bargain stocks. They may be looking to spot those shares that haven’t been doing a whole lot and are being generally overlooked by the investing world. Value investors may be searching for stocks with lower price to earnings ratios that possess higher dividend yields. Investors looking for growth stocks may be willing to shell out a little more for a stock that has the possibility of increasing EPS at a quicker pace. Some investors may favor one category of stocks over another, but they may need to find a combination at some point. As markets tend to move in cycles, it may be necessary to align the portfolio to the category that is best positioned to make consistent gains in the future.

This article is informational purposes only and should not be considered a recommendation to buy or sell Abbott Laboratories. 

Leave a Comment